Cargando…

Advances in mRNA therapeutics for cancer immunotherapy: From modification to delivery

RNA vaccines have demonstrated their ability to solve the issues posed by the COVID-19 pandemic. This success has led to the renaissance of research into mRNA and their nanoformulations as potential therapeutic modalities for various diseases. The potential of mRNA as a template for synthesizing pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Geonhee, Noh, Dahye, Lee, Hokyung, Lee, Sangmin, Kim, Sehoon, Yoon, Hong Yeol, Lee, Soo Hyeon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10290897/
https://www.ncbi.nlm.nih.gov/pubmed/37369262
http://dx.doi.org/10.1016/j.addr.2023.114973
_version_ 1785062585648807936
author Han, Geonhee
Noh, Dahye
Lee, Hokyung
Lee, Sangmin
Kim, Sehoon
Yoon, Hong Yeol
Lee, Soo Hyeon
author_facet Han, Geonhee
Noh, Dahye
Lee, Hokyung
Lee, Sangmin
Kim, Sehoon
Yoon, Hong Yeol
Lee, Soo Hyeon
author_sort Han, Geonhee
collection PubMed
description RNA vaccines have demonstrated their ability to solve the issues posed by the COVID-19 pandemic. This success has led to the renaissance of research into mRNA and their nanoformulations as potential therapeutic modalities for various diseases. The potential of mRNA as a template for synthesizing proteins and protein fragments for cancer immunotherapy is now being explored. Despite the promise, the use of mRNA in cancer immunotherapy is limited by challenges, such as low stability against extracellular RNases, poor delivery efficiency to the target organs and cells, short circulatory half-life, variable expression levels and duration. This review highlights recent advances in chemical modification and advanced delivery systems that are helping to address these challenges and unlock the biological and pharmacological potential of mRNA therapeutics in cancer immunotherapy. The review concludes by discussing future perspectives for mRNA-based cancer immunotherapy, which holds great promise as a next-generation therapeutic modality.
format Online
Article
Text
id pubmed-10290897
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-102908972023-06-26 Advances in mRNA therapeutics for cancer immunotherapy: From modification to delivery Han, Geonhee Noh, Dahye Lee, Hokyung Lee, Sangmin Kim, Sehoon Yoon, Hong Yeol Lee, Soo Hyeon Adv Drug Deliv Rev Article RNA vaccines have demonstrated their ability to solve the issues posed by the COVID-19 pandemic. This success has led to the renaissance of research into mRNA and their nanoformulations as potential therapeutic modalities for various diseases. The potential of mRNA as a template for synthesizing proteins and protein fragments for cancer immunotherapy is now being explored. Despite the promise, the use of mRNA in cancer immunotherapy is limited by challenges, such as low stability against extracellular RNases, poor delivery efficiency to the target organs and cells, short circulatory half-life, variable expression levels and duration. This review highlights recent advances in chemical modification and advanced delivery systems that are helping to address these challenges and unlock the biological and pharmacological potential of mRNA therapeutics in cancer immunotherapy. The review concludes by discussing future perspectives for mRNA-based cancer immunotherapy, which holds great promise as a next-generation therapeutic modality. Elsevier B.V. 2023-08 2023-06-25 /pmc/articles/PMC10290897/ /pubmed/37369262 http://dx.doi.org/10.1016/j.addr.2023.114973 Text en © 2023 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Han, Geonhee
Noh, Dahye
Lee, Hokyung
Lee, Sangmin
Kim, Sehoon
Yoon, Hong Yeol
Lee, Soo Hyeon
Advances in mRNA therapeutics for cancer immunotherapy: From modification to delivery
title Advances in mRNA therapeutics for cancer immunotherapy: From modification to delivery
title_full Advances in mRNA therapeutics for cancer immunotherapy: From modification to delivery
title_fullStr Advances in mRNA therapeutics for cancer immunotherapy: From modification to delivery
title_full_unstemmed Advances in mRNA therapeutics for cancer immunotherapy: From modification to delivery
title_short Advances in mRNA therapeutics for cancer immunotherapy: From modification to delivery
title_sort advances in mrna therapeutics for cancer immunotherapy: from modification to delivery
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10290897/
https://www.ncbi.nlm.nih.gov/pubmed/37369262
http://dx.doi.org/10.1016/j.addr.2023.114973
work_keys_str_mv AT hangeonhee advancesinmrnatherapeuticsforcancerimmunotherapyfrommodificationtodelivery
AT nohdahye advancesinmrnatherapeuticsforcancerimmunotherapyfrommodificationtodelivery
AT leehokyung advancesinmrnatherapeuticsforcancerimmunotherapyfrommodificationtodelivery
AT leesangmin advancesinmrnatherapeuticsforcancerimmunotherapyfrommodificationtodelivery
AT kimsehoon advancesinmrnatherapeuticsforcancerimmunotherapyfrommodificationtodelivery
AT yoonhongyeol advancesinmrnatherapeuticsforcancerimmunotherapyfrommodificationtodelivery
AT leesoohyeon advancesinmrnatherapeuticsforcancerimmunotherapyfrommodificationtodelivery